{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:31:05Z","timestamp":1793316665280,"version":"4.5.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13300-025-01738-3","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:23:57Z","timestamp":1745465037000},"page":"1155-1176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-4886","authenticated-orcid":false,"given":"Kevin","family":"Fernando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimear","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hinchliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. David","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"1738_CR1","doi-asserted-by":"publisher","unstructured":"Cardiovascular-Kidney-Metabolic Health: a presidential advisory from the American Heart Association [Internet]. https:\/\/doi.org\/10.1161\/CIR.0000000000001184. Accessed 17 Dec 2024.","DOI":"10.1161\/CIR.0000000000001184"},{"issue":"12","key":"1738_CR2","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1111\/dom.14829","volume":"24","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Maegawa H, Watada H, Yabe D, Node K, Murohara T, et al. Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24(12):2283\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1738_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2337\/db20211-13","volume":"2021","author":"MS Usman","year":"2021","unstructured":"Usman MS, Khan MS, Butler J. The interplay between diabetes, cardiovascular disease, and kidney disease. ADA Clin Compend. 2021;2021(1):13\u20138.","journal-title":"ADA Clin Compend"},{"key":"1738_CR4","doi-asserted-by":"publisher","unstructured":"A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association | Circulation [Internet]. https:\/\/doi.org\/10.1161\/CIR.0000000000001186?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org. Accessed 17 Dec 2024.","DOI":"10.1161\/CIR.0000000000001186?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org"},{"issue":"7","key":"1738_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/dom.14698","volume":"24","author":"A Norhammar","year":"2022","unstructured":"Norhammar A, Bodegard J, Eriksson JW, Haller H, Linssen GCM, Banerjee A, et al. Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: a multinational, observational study across 12 countries. Diabetes Obes Metab. 2022;24(7):1277\u201387.","journal-title":"Diabetes Obes Metab"},{"key":"1738_CR6","unstructured":"BHF CVD Statistics UK Factsheet January 2025 [Internet]. https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-cvd-statistics-uk-factsheet.pdf?rev=81a8015761aa4ced8bc39d7045202be5&hash=9D78ACBF5EB80FA8A9BE28C90BFBE171. Accessed 31 Jan 2025."},{"key":"1738_CR7","unstructured":"Diabetes UK [Internet]. Diabetes diagnoses double in the last 15 years. https:\/\/www.diabetes.org.uk\/about-us\/news-and-views\/diabetes-diagnoses-doubled-prevalence-2021. Accessed 17 Dec 2024."},{"key":"1738_CR8","unstructured":"Diabetes UK [Internet]. How many people in the UK have diabetes? https:\/\/www.diabetes.org.uk\/about-us\/about-the-charity\/our-strategy\/statistics. Accessed 17 Dec 2024."},{"issue":"11","key":"1738_CR9","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/ckj\/sfad139","volume":"16","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Iatridi F, Ferro C, Alexandrou ME, Fernandez-Fernandez B, Kanbay M, et al. Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). Clin Kidney J. 2023;16(11):1885\u2013907.","journal-title":"Clin Kidney J"},{"key":"1738_CR10","unstructured":"Burden of CVD | Background information | CVD risk assessment and management | CKS | NICE [Internet]. https:\/\/cks.nice.org.uk\/topics\/cvd-risk-assessment-management\/background-information\/burden-of-cvd\/. Accessed 17 Dec 2024."},{"key":"1738_CR11","unstructured":"Economics-of-Kidney-Disease-full-report_accessible.pdf [Internet]. https:\/\/www.kidneyresearchuk.org\/wp-content\/uploads\/2023\/06\/Economics-of-Kidney-Disease-full-report_accessible.pdf. Accessed 17 Dec 2024."},{"key":"1738_CR12","unstructured":"Stiebahl S. Obesity statistics. 2025. https:\/\/commonslibrary.parliament.uk\/research-briefings\/sn03336\/. Accessed 10 Mar 2025."},{"issue":"10258","key":"1738_CR13","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"issue":"10159","key":"1738_CR14","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet Lond Engl. 2018;392(10159):2052\u201390.","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"1738_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15326","volume":"41","author":"N Hex","year":"2024","unstructured":"Hex N, MacDonald R, Pocock J, Uzdzinska B, Taylor M, Atkin M, et al. Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model. Diabet Med. 2024;41(9): e15326.","journal-title":"Diabet Med"},{"key":"1738_CR16","unstructured":"GOV.UK [Internet]. Health matters: obesity and the food environment. https:\/\/www.gov.uk\/government\/publications\/health-matters-obesity-and-the-food-environment\/health-matters-obesity-and-the-food-environment-2. Accessed 29 Jan 2025."},{"issue":"14","key":"1738_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jacc.2023.01.042","volume":"81","author":"EJ Brandt","year":"2023","unstructured":"Brandt EJ, Tobb K, Cambron JC, Ferdinand K, Douglass P, Nguyen PK, et al. Assessing and addressing social determinants of cardiovascular health: JACC state-of-the-art review. J Am Coll Cardiol. 2023;81(14):1368\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1738_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhip.2024.100466","volume":"1","author":"H Painter","year":"2024","unstructured":"Painter H, Parry E, McCann L, Dehn Lunn A, Ford J. Social needs screening in primary care: a tool in the fight for health equity? Public Health Pract. 2024;1(7): 100466.","journal-title":"Public Health Pract"},{"key":"1738_CR19","unstructured":"A framework for NHS action on social determinants of health | The Health Foundation [Internet]. 2022. https:\/\/www.health.org.uk\/reports-and-analysis\/briefings\/a-framework-for-nhs-action-on-social-determinants-of-health. Accessed 26 Mar 2025."},{"issue":"733","key":"1738_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3399\/bjgp23X734649","volume":"73","author":"R Fisher","year":"2023","unstructured":"Fisher R, Gottlieb LM, Marchis ED, Alderwick H. Assessing patients\u2019 social risks: what can England learn from emerging evidence in the US? Br J Gen Pract. 2023;73(733):370\u20132.","journal-title":"Br J Gen Pract"},{"issue":"9","key":"1738_CR21","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ekir.2024.05.033","volume":"9","author":"ZA Massy","year":"2024","unstructured":"Massy ZA, Drueke TB. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations. Kidney Int Rep. 2024;9(9):2608\u201318.","journal-title":"Kidney Int Rep"},{"issue":"22","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","volume":"31","author":"M Marassi","year":"2023","unstructured":"Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;31(22):195.","journal-title":"Cardiovasc Diabetol"},{"key":"1738_CR23","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2023;47(Supplement_1):S179\u2013218."},{"issue":"39","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"key":"1738_CR25","unstructured":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | Diabetes Care | American Diabetes Association [Internet]. https:\/\/diabetesjournals.org\/care\/article\/45\/11\/2753\/147671\/Management-of-Hyperglycemia-in-Type-2-Diabetes. Accessed 17 Dec 2024."},{"issue":"12","key":"1738_CR26","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in Chronic Kidney Disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"12","key":"1738_CR27","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/s11255-024-04142-1","volume":"56","author":"L Zhou","year":"2024","unstructured":"Zhou L, Li W. Effectiveness and safety of finerenone in Chinese CKD patients without diabetes: a retrospective, real-world study. Int Urol Nephrol. 2024;56(12):3877\u201385.","journal-title":"Int Urol Nephrol"},{"key":"1738_CR28","unstructured":"Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI, Lam CSP, Neuen BL, et al. Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. Nephrol Dial Transplant. 2024;gfae132."},{"issue":"1","key":"1738_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/biomedicines13010135","volume":"13","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis N, Nikolaou M. Integrated management of cardiovascular\u2013renal\u2013hepatic\u2013metabolic syndrome: expanding roles of SGLT2is, GLP-1RAs, and GIP\/GLP-1RAs. Biomedicines. 2025;13(1):135.","journal-title":"Biomedicines"},{"issue":"2","key":"1738_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"24","key":"1738_CR31","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"key":"1738_CR32","unstructured":"TCTMD.com [Internet]. 2024. SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients. https:\/\/www.tctmd.com\/news\/soul-oral-semaglutide-cuts-cv-events-diabetic-patients. Accessed 29 Jan 2025."},{"issue":"202","key":"1738_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110770","volume":"1","author":"TT V\u00e1rkonyi","year":"2023","unstructured":"V\u00e1rkonyi TT, P\u00f3sa A, P\u00e1v\u00f3 N, Pavo I. Perspectives on weight control in diabetes\u2014Tirzepatide. Diabetes Res Clin Pract. 2023;1(202): 110770.","journal-title":"Diabetes Res Clin Pract"},{"key":"1738_CR34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med [Internet]. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med [Internet]"},{"issue":"4","key":"1738_CR35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"key":"1738_CR36","unstructured":"U.S FDA. FDA. FDA; 2024. FDA Approves First Medication for Obstructive Sleep Apnea. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea. Accessed 21 Jan 2025."},{"issue":"13","key":"1738_CR37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"issue":"7","key":"1738_CR38","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463\u201376.","journal-title":"Kidney Int Rep"},{"key":"1738_CR39","unstructured":"Finerenone | Drugs | BNF content published by NICE [Internet]. https:\/\/bnf.nice.org.uk\/drugs\/finerenone\/. Accessed 17 Dec 2024."},{"issue":"23","key":"1738_CR40","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"1738_CR41","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"16","key":"1738_CR42","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"4","key":"1738_CR43","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","volume":"38","author":"JB Green","year":"2022","unstructured":"Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2022;38(4):894\u2013903.","journal-title":"Nephrol Dial Transplant"},{"key":"1738_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110908","volume":"204","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Ji L, Mathieu C, et al. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract. 2023;204: 110908.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1738_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/jcm12010145","volume":"12","author":"JJ Gorgojo-Mart\u00ednez","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, Castro A, Cebri\u00e1n-Cuenca A, de Torres-S\u00e1nchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145.","journal-title":"J Clin Med"},{"issue":"8","key":"1738_CR46","first-page":"e66408","volume":"16","author":"S Chauhan","year":"2024","unstructured":"Chauhan S, Diaz V, Ogbu IR, Sanchez JRP, Manov AE, Shah P. empagliflozin-associated euglycemic diabetic ketoacidosis masked by urinary tract infection. Cureus. 2024;16(8):e66408.","journal-title":"Cureus"},{"issue":"1","key":"1738_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol JASN. 2022;33(1):225\u201337.","journal-title":"J Am Soc Nephrol JASN"},{"issue":"10322","key":"1738_CR48","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","volume":"399","author":"I Lingvay","year":"2022","unstructured":"Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet Lond Engl. 2022;399(10322):394\u2013405.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"1738_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3803\/EnM.2024.1942","volume":"39","author":"A Jakubowska","year":"2024","unstructured":"Jakubowska A, le Roux CW, Viljoen A. The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor\u2014an update. Endocrinol Metab. 2024;39(1):12\u201322.","journal-title":"Endocrinol Metab"},{"issue":"10","key":"1738_CR50","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1021\/acsmedchemlett.9b00429","volume":"10","author":"AF Abdel-Magid","year":"2019","unstructured":"Abdel-Magid AF. Lysophosphatidic acid receptor 1 antagonists for the treatment of fibrosis. ACS Med Chem Lett. 2019;10(10):1378\u20139.","journal-title":"ACS Med Chem Lett"},{"issue":"63","key":"1738_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101533","volume":"7","author":"PJ Knerr","year":"2022","unstructured":"Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hj\u00f8llund KR, He Y, et al. Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;7(63): 101533.","journal-title":"Mol Metab"},{"key":"1738_CR52","doi-asserted-by":"crossref","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. eClinicalMedicine [Internet]. 2024 Sep 1;75. https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(24)00361-4\/fulltext. Accessed 17 Dec 2024.","DOI":"10.1016\/j.eclinm.2024.102782"},{"issue":"10401","key":"1738_CR53","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet Lond Engl. 2023;402(10401):529\u201344.","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"1738_CR54","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9.","journal-title":"Cell Metab"},{"issue":"28","key":"1738_CR55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204174119","volume":"119","author":"AA Raja","year":"2022","unstructured":"Raja AA, Wakimoto H, DeLaughter DM, Reichart D, Gorham J, Conner DA, et al. Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse model. Proc Natl Acad Sci USA. 2022;119(28): e2204174119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1738_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jphs.2022.05.003","volume":"149","author":"T Naruse","year":"2022","unstructured":"Naruse T, Otake H, Takahashi T. Effects of a lysophosphatidic acid receptor 1 antagonist on hypertensive renal injury in Dahl-Iwai salt-sensitive rats. J Pharmacol Sci. 2022;149(4):179\u201388.","journal-title":"J Pharmacol Sci"},{"issue":"7","key":"1738_CR57","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/j.1476-5381.2010.00828.x","volume":"160","author":"J Swaney","year":"2010","unstructured":"Swaney J, Chapman C, Correa L, Stebbins K, Bundey R, Prodanovich P, et al. A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol. 2010;160(7):1699\u2013713.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1738_CR58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12931-022-01980-4","volume":"23","author":"BE Decato","year":"2022","unstructured":"Decato BE, Leeming DJ, Sand JMB, Fischer A, Du S, Palmer SM, et al. LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. Respir Res. 2022;23(1):61.","journal-title":"Respir Res"},{"issue":"12","key":"1738_CR59","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN). Clin J Am Soc Nephrol CJASN. 2020;15(12):1715\u201327.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"1738_CR60","unstructured":"AstraZeneca. A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function [Internet]. clinicaltrials.gov; 2024 Dec. Report No.: NCT06307652. https:\/\/clinicaltrials.gov\/study\/NCT06307652. Accessed 21 Jan 2025."},{"key":"1738_CR61","unstructured":"AstraZeneca. A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria [Internet]. clinicaltrials.gov; 2025 Jan. Report No.: NCT06350123. https:\/\/clinicaltrials.gov\/study\/NCT06350123. Accessed 21 Jan 2025."},{"issue":"7","key":"1738_CR62","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","volume":"21","author":"W Sun","year":"2016","unstructured":"Sun W, Sanderson P, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discov Today. 2016;21(7):1189\u201395.","journal-title":"Drug Discov Today"},{"issue":"10416","key":"1738_CR63","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet. 2023;402(10416):2004\u201317.","journal-title":"Lancet"},{"key":"1738_CR64","unstructured":"CDEK. EASi-KIDNEYTM (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) [Internet]. https:\/\/cdek.pharmacy.purdue.edu\/trial\/NCT06531824\/. Accessed 21 Jan 2025."},{"issue":"3","key":"1738_CR65","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wong VWS, Ratziu V, Bugianesi E, Francque S, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"8","key":"1738_CR66","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35(8):697\u2013707.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1738_CR67","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1738_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100192","volume":"2","author":"P Burra","year":"2020","unstructured":"Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep. 2020;2(6): 100192.","journal-title":"JHEP Rep"},{"issue":"6","key":"1738_CR69","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/CIRCRESAHA.119.312321","volume":"126","author":"AJ Mouton","year":"2020","unstructured":"Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction. Circ Res. 2020;126(6):789\u2013806.","journal-title":"Circ Res"},{"issue":"1","key":"1738_CR70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jchf.2019.09.002","volume":"8","author":"M Packer","year":"2020","unstructured":"Packer M. HFpEF is the substrate for stroke in obesity and diabetes independent of atrial fibrillation. JACC Heart Fail. 2020;8(1):35\u201342.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"1738_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.856602","volume":"1","author":"W Lai","year":"2022","unstructured":"Lai W, Zhao X, Yu S, Mai Z, Zhou Y, Huang Z, et al. Chronic kidney disease increases risk of incident HFrEF following percutaneous coronary intervention. Front Cardiovasc Med. 2022;1(9): 856602.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1738_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000520909","volume":"12","author":"K Vijay","year":"2021","unstructured":"Vijay K, Neuen BL, Lerma EV. Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities. Cardiorenal Med. 2021;12(1):1\u201310.","journal-title":"Cardiorenal Med"},{"key":"1738_CR73","unstructured":"Overview | Chronic heart failure in adults: diagnosis and management | Guidance | NICE [Internet]. NICE; 2018. https:\/\/www.nice.org.uk\/guidance\/ng106. Accessed 17 Dec 2024."},{"issue":"13","key":"1738_CR74","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029071","volume":"12","author":"D D\u2019Amario","year":"2023","unstructured":"D\u2019Amario D, Rodolico D, Delvinioti A, Laborante R, Iacomini C, Masciocchi C, et al. Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge. J Am Heart Assoc. 2023;12(13): e029071.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1738_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001585","volume":"8","author":"S Straw","year":"2021","unstructured":"Straw S, McGinlay M, Witte KK. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart. 2021;8(1): e001585.","journal-title":"Open Heart"},{"key":"1738_CR76","unstructured":"BrJCardiol. Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy [Internet]. https:\/\/bjcardio.co.uk\/2022\/01\/foundational-drugs-for-hfref-the-growing-evidence-for-a-rapid-sequencing-strategy\/. Accessed 30 Jan 2025."},{"issue":"11","key":"1738_CR77","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease. Circulation. 2021;143(11):1157\u201372.","journal-title":"Circulation"},{"issue":"1","key":"1738_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diseases12010014","volume":"12","author":"P Krisanapan","year":"2024","unstructured":"Krisanapan P, Sanpawithayakul K, Pattharanitima P, Thongprayoon C, Miao J, Mao MA, et al. Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis. Diseases. 2024;12(1):14.","journal-title":"Diseases"},{"key":"1738_CR79","unstructured":"Gansevoort R. A randomized controlled clinical trial to assess the effect of dapagliflozin on renal and cardiovascular outcomes in patients with severe chronic kidney disease [Internet]. clinicaltrials.gov; 2024 May. Report No.: NCT05374291. https:\/\/clinicaltrials.gov\/study\/NCT05374291. Accessed 21 Jan 2025."},{"key":"1738_CR80","unstructured":"Rossignol P. Spironolactone failed to reduce major adverse cardiac effects in patients with CKD on haemodialysis [Internet]. Medical Conferences. 2023. https:\/\/conferences.medicom-publishers.com\/specialisation\/nephrology\/asn-2023\/spironolactone-failed-to-reduce-major-adverse-cardiac-effects-in-patients-with-ckd-on-haemodialysis-2\/. Accessed 27 Mar 2025."},{"key":"1738_CR81","unstructured":"Barton C, Sturge G, Harker R. The UK\u2019s changing population. 2024 Jul 16. https:\/\/commonslibrary.parliament.uk\/the-uks-changing-population\/. Accessed 17 Dec 2024."},{"issue":"5","key":"1738_CR82","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jacc.2021.11.029","volume":"79","author":"N Ijaz","year":"2022","unstructured":"Ijaz N, Buta B, Xue QL, Mohess DT, Bushan A, Tran H, et al. Interventions for frailty among older adults with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(5):482\u2013503.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1738_CR83","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s13300-021-01035-9","volume":"12","author":"WD Strain","year":"2021","unstructured":"Strain WD, Down S, Brown P, Puttanna A, Sinclair A. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021;12(5):1227\u201347.","journal-title":"Diabetes Ther"},{"issue":"1","key":"1738_CR84","doi-asserted-by":"publisher","first-page":"72","DOI":"10.7861\/clinmedicine.11-1-72","volume":"11","author":"A Clegg","year":"2011","unstructured":"Clegg A, Young J. The frailty syndrome. Clin Med. 2011;11(1):72\u20135.","journal-title":"Clin Med"},{"key":"1738_CR85","unstructured":"Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes\u2014ClinicalKey [Internet]. https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S0895435612000844. Accessed 29 Jan 2025."},{"issue":"349","key":"1738_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7013","volume":"21","author":"D Gnjidic","year":"2014","unstructured":"Gnjidic D, Couteur DGL, Hilmer SN. Discontinuing drug treatments. BMJ. 2014;21(349): g7013.","journal-title":"BMJ"},{"issue":"6","key":"1738_CR87","doi-asserted-by":"publisher","first-page":"820","DOI":"10.7326\/M21-4776","volume":"175","author":"JH Butt","year":"2022","unstructured":"Butt JH, Dewan P, Merkely B, Belohl\u00e1vek J, Dro\u017cd\u017c J, Kitakaze M, et al. Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial. Ann Intern Med. 2022;175(6):820\u201330.","journal-title":"Ann Intern Med"},{"key":"1738_CR88","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ahj.2016.12.012","volume":"185","author":"GR Reeves","year":"2017","unstructured":"Reeves GR, Whellan DJ, Duncan P, O\u2019Connor CM, Pastva AM, Eggebeen JD, et al. Rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial: design and rationale. Am Heart J. 2017;185:130\u20139.","journal-title":"Am Heart J"},{"key":"1738_CR89","doi-asserted-by":"crossref","unstructured":"Goggins S. British Journal of Nursing. 2023. The importance of a comprehensive geriatric assessment for older people admitted onto a virtual ward. https:\/\/www.britishjournalofnursing.com\/content\/professional\/the-importance-of-a-comprehensive-geriatric-assessment-for-older-people-admitted-onto-a-virtual-ward\/. Accessed 31 Jan 2025.","DOI":"10.12968\/bjon.2023.32.18.882"},{"key":"1738_CR90","unstructured":"Definition and diagnostic criteria of clinical obesity\u2014ClinicalKey [Internet]. https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S2213858724003164. Accessed 30 Jan 2025."},{"key":"1738_CR91","unstructured":"National Chronic Kidney Disease Audit\/\/National Report: Part 2 December 2017 [Internet]. https:\/\/www.lshtm.ac.uk\/media\/9951. Accessed 14 Dec 2023."},{"key":"1738_CR92","unstructured":"Scenario: Management | Management | Obesity | CKS | NICE [Internet]. https:\/\/cks.nice.org.uk\/topics\/obesity\/management\/management\/. Accessed 17 Dec 2024."},{"key":"1738_CR93","unstructured":"NICE CG189. Obesity: identification, assessment and management. https:\/\/www.nice.org.uk\/guidance\/cg189. Accessed 3 Feb 2025."},{"issue":"5","key":"1738_CR94","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(20)30102-9","volume":"8","author":"C Albury","year":"2020","unstructured":"Albury C, Strain WD, Brocq SL, Logue J, Lloyd C, Tahrani A. The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement. Lancet Diabetes Endocrinol. 2020;8(5):447\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1738_CR95","unstructured":"Let\u2019s Talk About Weight: A step-by-step guide to brief interventions with adults for health and care professionals [Internet]. https:\/\/assets.publishing.service.gov.uk\/media\/5b8d54d2e5274a0bd7d11928\/weight_management_toolkit_Let_s_talk_about_weight.pdf. Accessed 17 Dec 2024."},{"issue":"14","key":"1738_CR96","doi-asserted-by":"publisher","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","volume":"1","author":"JY Wang","year":"2023","unstructured":"Wang JY, Wang QW, Yang XY, Yang W, Li DR, Jin JY, et al. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Front Endocrinol. 2023;1(14):1085799.","journal-title":"Front Endocrinol"},{"key":"1738_CR97","unstructured":"NICE NG246. Overview | Overweight and obesity management | Guidance | NICE [Internet]. NICE; 2025. https:\/\/www.nice.org.uk\/guidance\/ng246. Accessed 27 Mar 2025."},{"issue":"9","key":"1738_CR98","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/archdischild-2021-321864","volume":"107","author":"REJ Besser","year":"2022","unstructured":"Besser REJ, Ng SM, Gregory JW, Dayan CM, Randell T, Barrett T. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch Dis Child. 2022;107(9):790\u20135.","journal-title":"Arch Dis Child"},{"key":"1738_CR99","unstructured":"Statista [Internet]. Diabetes in England and Wales by type 2023\/24. https:\/\/www.statista.com\/statistics\/386742\/individuals-with-diabetes-by-type-in-england-and-wales\/. Accessed 30 Jan 2025."},{"issue":"10","key":"1738_CR100","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1111\/dom.15773","volume":"26","author":"MA Escobar Vasco","year":"2024","unstructured":"Escobar Vasco MA, Fantaye SH, Raghunathan S, Solis-Herrera C. The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease. Diabetes Obes Metab. 2024;26(10):4135\u201346.","journal-title":"Diabetes Obes Metab"},{"key":"1738_CR101","unstructured":"Type 1 diabetes | Treatment summaries | BNF content published by NICE [Internet]. https:\/\/bnf.nice.org.uk\/treatment-summaries\/type-1-diabetes\/. Accessed 17 Dec 2024."},{"issue":"12","key":"1738_CR102","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","volume":"7","author":"SI Taylor","year":"2019","unstructured":"Taylor SI, Blau JE, Rother KI, Beitelshees AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits versus risks. Lancet Diabetes Endocrinol. 2019;7(12):949\u201358.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1738_CR103","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dc20-2839","volume":"44","author":"R Krist\u00f3fi","year":"2021","unstructured":"Krist\u00f3fi R, Bodegard J, Norhammar A, Thuresson M, Nathanson D, Nystr\u00f6m T, et al. Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study. Diabetes Care. 2021;44(5):1211\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"1738_CR104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41406-019-0053-x","volume":"26","author":"N Nwosu","year":"2019","unstructured":"Nwosu N. Obstructive sleep apnoea: important things to know. BDJ Stud. 2019;26(3):40\u20132.","journal-title":"BDJ Stud"},{"issue":"10","key":"1738_CR105","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.2337\/dc18-0675","volume":"41","author":"T Huang","year":"2018","unstructured":"Huang T, Lin BM, Stampfer MJ, Tworoger SS, Hu FB, Redline S. A population-based study of the bidirectional association between obstructive sleep apnea and type 2 diabetes in three prospective US cohorts. Diabetes Care. 2018;41(10):2111\u20139.","journal-title":"Diabetes Care"},{"issue":"109","key":"1738_CR106","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.sleep.2023.05.020","volume":"1","author":"M Liu","year":"2023","unstructured":"Liu M, Heizhati M, Li N, Lin M, Gan L, Zhu Q, et al. The relationship between obstructive sleep apnea and risk of renal impairment in patients with hypertension, a longitudinal study. Sleep Med. 2023;1(109):18\u201324.","journal-title":"Sleep Med"},{"issue":"11","key":"1738_CR107","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3390\/jcm8111872","volume":"8","author":"G Oscullo","year":"2019","unstructured":"Oscullo G, Torres G, Campos-Rodriguez F, Posadas T, Reina-Gonz\u00e1lez A, Sapi\u00f1a-Beltr\u00e1n E, et al. Resistant\/refractory hypertension and sleep apnoea: current knowledge and future challenges. J Clin Med. 2019;8(11):1872.","journal-title":"J Clin Med"},{"key":"1738_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00440\/full","author":"SN Framnes","year":"2018","unstructured":"Framnes SN, Arble DM. The bidirectional relationship between obstructive sleep apnea and metabolic disease. Front Endocrinol [Internet]. 2018. https:\/\/doi.org\/10.3389\/fendo.2018.00440\/full.","journal-title":"Front Endocrinol [Internet]"},{"issue":"7","key":"1738_CR109","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jacc.2016.11.069","volume":"69","author":"S Javaheri","year":"2017","unstructured":"Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841\u201358.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1738_CR110","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.chest.2019.09.004","volume":"157","author":"CH Lin","year":"2020","unstructured":"Lin CH, Lurie RC, Lyons OD. Sleep apnea and chronic kidney disease: a state-of-the-art review. Chest. 2020;157(3):673\u201385.","journal-title":"Chest"},{"key":"1738_CR111","unstructured":"NICE NG202. Overview | Obstructive sleep apnoea\/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | Guidance | NICE [Internet]. NICE; 2021. https:\/\/www.nice.org.uk\/guidance\/ng202. Accessed 21 Jan 2025."},{"key":"1738_CR112","unstructured":"Artificial Intelligence for Cardiovascular Care\u2014Part 1: advances\u2014ClinicalKey [Internet]. https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S0735109724067421. Accessed 17 Dec 2024."},{"issue":"12","key":"1738_CR113","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/ckj\/sfad182","volume":"16","author":"L Fayos De Ariz\u00f3n","year":"2023","unstructured":"Fayos De Ariz\u00f3n L, Viera ER, Pilco M, Perera A, De Maeztu G, Nicolau A, et al. Artificial intelligence: a new field of knowledge for nephrologists? Clin Kidney J. 2023;16(12):2314\u201326.","journal-title":"Clin Kidney J"},{"issue":"14","key":"1738_CR114","doi-asserted-by":"publisher","first-page":"26503","DOI":"10.1038\/s41598-024-78553-6","volume":"3","author":"W DeGroat","year":"2024","unstructured":"DeGroat W, Abdelhalim H, Peker E, Sheth N, Narayanan R, Zeeshan S, et al. Multimodal AI\/ML for discovering novel biomarkers and predicting disease using multi-omics profiles of patients with cardiovascular diseases. Sci Rep. 2024;3(14):26503.","journal-title":"Sci Rep"},{"issue":"1","key":"1738_CR115","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s40001-023-01065-y","volume":"28","author":"X Sun","year":"2023","unstructured":"Sun X, Yin Y, Yang Q, Huo T. Artificial intelligence in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur J Med Res. 2023;28(1):242.","journal-title":"Eur J Med Res"},{"issue":"1","key":"1738_CR116","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/sdi.12915","volume":"34","author":"S Chaudhuri","year":"2021","unstructured":"Chaudhuri S, Long A, Zhang H, Monaghan C, Larkin JW, Kotanko P, et al. Artificial intelligence enabled applications in kidney disease. Semin Dial. 2021;34(1):5\u201316.","journal-title":"Semin Dial"},{"issue":"1","key":"1738_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-023-00933-5","volume":"6","author":"F Mohsen","year":"2023","unstructured":"Mohsen F, Al-Absi HRH, Yousri NA, El Hajj N, Shah Z. A scoping review of artificial intelligence-based methods for diabetes risk prediction. Npj Digit Med. 2023;6(1):1\u201315.","journal-title":"Npj Digit Med"},{"issue":"1","key":"1738_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44325-024-00031-9","volume":"1","author":"A Mihan","year":"2024","unstructured":"Mihan A, Pandey A, Van Spall HGC. Artificial intelligence bias in the prediction and detection of cardiovascular disease. Npj Cardiovasc Health. 2024;1(1):1\u20138.","journal-title":"Npj Cardiovasc Health"},{"issue":"7","key":"1738_CR119","doi-asserted-by":"publisher","first-page":"257","DOI":"10.31083\/j.rcm2507257","volume":"25","author":"H Liang","year":"2024","unstructured":"Liang H, Zhang H, Wang J, Shao X, Wu S, Lyu S, et al. The application of artificial intelligence in atrial fibrillation patients: from detection to treatment. Rev Cardiovasc Med. 2024;25(7):257.","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"1738_CR120","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ceh.2021.11.003","volume":"1","author":"L Yao","year":"2021","unstructured":"Yao L, Zhang H, Zhang M, Chen X, Zhang J, Huang J, et al. Application of artificial intelligence in renal disease. Clin EHealth. 2021;1(4):54\u201361.","journal-title":"Clin EHealth"},{"issue":"19","key":"1738_CR121","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3390\/diagnostics14192119","volume":"14","author":"N Alowidi","year":"2024","unstructured":"Alowidi N, Ali R, Sadaqah M, Naemi FMA. Advancing kidney transplantation: a machine learning approach to enhance donor-recipient matching. Diagnostics. 2024;14(19):2119.","journal-title":"Diagnostics"},{"issue":"1","key":"1738_CR122","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/biomedinformatics4010037","volume":"4","author":"L Ramalhete","year":"2024","unstructured":"Ramalhete L, Almeida P, Ferreira R, Abade O, Teixeira C, Ara\u00fajo R. Revolutionizing kidney transplantation: connecting machine learning and artificial intelligence with next-generation healthcare\u2014from algorithms to allografts. BioMedInformatics. 2024;4(1):673\u201389.","journal-title":"BioMedInformatics"},{"issue":"7","key":"1738_CR123","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1007\/s00125-021-05444-0","volume":"64","author":"L Chan","year":"2021","unstructured":"Chan L, Nadkarni GN, Fleming F, McCullough JR, Connolly P, Mosoyan G, et al. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. Diabetologia. 2021;64(7):1504\u201315.","journal-title":"Diabetologia"},{"issue":"2","key":"1738_CR124","first-page":"290","volume":"2","author":"X Jin","year":"2023","unstructured":"Jin X, Cai A, Xu T, Zhang X. Artificial intelligence biosensors for continuous glucose monitoring. Interdiscip Mater. 2023;2(2):290\u2013307.","journal-title":"Interdiscip Mater"},{"issue":"4","key":"1738_CR125","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cmet.2024.02.002","volume":"36","author":"ED Muse","year":"2024","unstructured":"Muse ED, Topol EJ. Transforming the cardiometabolic disease landscape: multimodal AI-powered approaches in prevention and management. Cell Metab. 2024;36(4):670\u201383.","journal-title":"Cell Metab"},{"issue":"5","key":"1738_CR126","first-page":"e61312","volume":"16","author":"V Bhaltadak","year":"2024","unstructured":"Bhaltadak V, Ghewade B, Yelne S. A comprehensive review on advancements in wearable technologies: revolutionizing cardiovascular medicine. Cureus. 2024;16(5):e61312.","journal-title":"Cureus."},{"issue":"5","key":"1738_CR127","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/CIRCRESAHA.122.322389","volume":"132","author":"A Hughes","year":"2023","unstructured":"Hughes A, Shandhi MMH, Master H, Dunn J, Brittain E. Wearable devices in cardiovascular medicine. Circ Res. 2023;132(5):652\u201370.","journal-title":"Circ Res"},{"issue":"10","key":"1738_CR128","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36876","volume":"6","author":"G Aleppo","year":"2023","unstructured":"Aleppo G, Gal RL, Raghinaru D, Kruger D, Beck RW, Bergenstal RM, et al. Comprehensive telehealth model to support diabetes self-management. JAMA Netw Open. 2023;6(10): e2336876.","journal-title":"JAMA Netw Open"},{"key":"1738_CR129","first-page":"e4050","volume":"31","author":"OAE de Almeida","year":"2024","unstructured":"de Almeida OAE, de Lima MEF, Santos WS, Silva BLM. Telehealth strategies in the care of people with chronic kidney disease: integrative review. Rev Lat Am Enfermagem. 2024;31:e4050.","journal-title":"Rev Lat Am Enfermagem"},{"issue":"1","key":"1738_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpdig.2024.11.002","volume":"3","author":"T Ellis","year":"2025","unstructured":"Ellis T, Kwon AJ, Hong MY. The effectiveness of telehealth intervention on chronic kidney disease management in adults: a systematic review. Mayo Clin Proc Digit Health. 2025;3(1): 100181.","journal-title":"Mayo Clin Proc Digit Health"},{"issue":"1","key":"1738_CR131","first-page":"67","volume":"4","author":"TN Jackson","year":"2023","unstructured":"Jackson TN, Sreedhara M, Bostic M, Spafford M, Popat S, Lowe Beasley K, et al. Telehealth use to address cardiovascular disease and hypertension in the united states: a systematic review and meta-analysis, 2011\u20132021. Telemed Rep. 2023;4(1):67\u201386.","journal-title":"Telemed Rep"},{"issue":"19","key":"1738_CR132","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.3390\/jcm12196200","volume":"12","author":"EA Kobe","year":"2023","unstructured":"Kobe EA, McVeigh T, Hameed I, Fudim M. Heart failure remote monitoring: a review and implementation how-to. J Clin Med. 2023;12(19):6200.","journal-title":"J Clin Med"},{"key":"1738_CR133","unstructured":"OpenSAFELY: About OpenSAFELY [Internet]. https:\/\/www.opensafely.org\/about\/. Accessed 22 Jan 2025"},{"key":"1738_CR134","unstructured":"CVDPREVENT [Internet]. CVDPREVENT. https:\/\/www.cvdprevent.nhs.uk. Accessed 22 Jan 2025"},{"key":"1738_CR135","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04165-8","author":"A Simeri","year":"2024","unstructured":"Simeri A, Pezzi G, Arena R, Papalia G, Szili-Torok T, Greco R, et al. Artificial intelligence in chronic kidney diseases: methodology and potential applications. Int Urol Nephrol [Internet]. 2024. https:\/\/doi.org\/10.1007\/s11255-024-04165-8.","journal-title":"Int Urol Nephrol [Internet]"},{"issue":"24","key":"1738_CR136","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.jacc.2024.03.401","volume":"83","author":"SS Jain","year":"2024","unstructured":"Jain SS, Elias P, Poterucha T, Randazzo M, Lopez Jimenez F, Khera R, et al. Artificial intelligence in cardiovascular care\u2014part 2: applications. J Am Coll Cardiol. 2024;83(24):2487\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"1738_CR137","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12911-023-02162-y","volume":"20","author":"A Sauerbrei","year":"2023","unstructured":"Sauerbrei A, Kerasidou A, Lucivero F, Hallowell N. The impact of artificial intelligence on the person-centred, doctor-patient relationship: some problems and solutions. BMC Med Inform Decis Mak. 2023;20(23):73.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1738_CR138","unstructured":"GOV.UK [Internet]. Impact of AI on the regulation of medical products. https:\/\/www.gov.uk\/government\/publications\/impact-of-ai-on-the-regulation-of-medical-products. Accessed 21 Jan 2025."},{"key":"1738_CR139","unstructured":"Takhar EA Julia Gillert, Jaspreet. Healthcare & Life Sciences Blog. 2024. MHRA launches AI Airlock to address challenges for regulating medical devices that use Artificial Intelligence. https:\/\/healthcarelifesciences.bakermckenzie.com\/2024\/05\/10\/mhra-launches-ai-airlock-to-address-challenges-for-regulating-medical-devices-that-use-artificial-intelligence\/. Accessed 21 Jan 2025."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01738-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:03:17Z","timestamp":1747458197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01738-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":139,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01738-3","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marc Evans is an Editor-in-Chief of Diabetes Therapy. Marc Evans was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. W. David Strain is an Editorial Board member of Diabetes Therapy. W. David Strain was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kevin Fernando, Derek Connolly, Eimear Darcy, William Hinchliffe and Patrick Holmes have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}}]}}